Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset, IP-001, in multiple solid tumor indications. This multinational clinical trial, denominated alternately as IP-IIO or INJECTABLE-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal...
Tomas Hode, PhD, Co-Founder, CIO, and President at @Immunophotonics, Inc. will be attending the Society of Interventional Oncology (SIO) 2023 annual scientific meeting January 19 – 23, in Washington, DC. Tomas will be connecting with interventional oncology professionals from around the world and learning about the latest developments in improving cancer care alongside medical, surgical...
A poster summarizing the results of the Phase 1b portion of the study SAKK 66/17 concerning the combination of thermal ablation with Immunophotonics’s lead asset, IP-001TM, in patients with advanced solid tumors was presented at the ESMO Immuno-Oncology Congress on December 7-9, 2022, in Geneva, Switzerland. The ESMO Congress is one of Europe’s premier events...
Our networking is well underway for the JPM 2023. Attending the annual summit Lu Alleruzzo at JPM Healthcare Conference, Theresa Visarius at JPM Biotech Showcase, and Tomas Hode at RESI, in San Francisco January 9 -12, 2023.
We are grateful to Johnson & Johnson Innovation for funding this vital work and are honored to advance medicine for our veterans and military community. This grant will provide Immunophotonics with the opportunity to expand the use of IP-001 into a previously untested combination with chemotherapy as a means of inducing systemic anti-tumor immune responses,...
Immunophotonics, Inc is proud to have been selected by YoungStartup Ventures to present at the Florida Venture Summit in Miami on December 6th & 7th. Lu Alleruzzo, CEO of Immunophotonics’ will be attending and presenting.
Congratulations to Professor Wei Chen and his lab at the University of Oklahoma for their publication in one of the top ranked oncology and immunology peer-reviewed journals, the Journal for ImmunoTherapy of Cancer (JITC), on their paper, “Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors”. Check out this key publication on how ablation...
Immunophotonics, Inc. would like to congratulate Wei Chen, Ph.D. on his recently awarded Grant by the National Cancer Institute of Health’s (NIH) National Cancer Institute for pancreatic cancer research. Check out the Official Press Release
Dr. Theresa Visarius, Immunophotonics Vice President of Business Development and Managing Director of Immunophotonics Switzerland will be attending Bio-Europe 2022 October 24th to 26th.
Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc., will be attending the BioPharm America 2022 conference in Boston on September 28 & 29th.
